GPCR250417P40000
- 19.10
- 0.000.00%
Structure Therapeutics Newsroom
Trending Stocks Today | Tenon Medical Surges 51.33% Post-Market
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Express News | Viking Therapeutics Shares up 11.1%, Structure Therapeutics Shares up 9%
Roche, Zealand Pharma Enter $5.3B License Deal for Obesity Treatment
We're Hopeful That Structure Therapeutics (NASDAQ:GPCR) Will Use Its Cash Wisely
Viking, Other Obesity Players Fall Following Novo Nordisk CagriSema Results
Novo Nordisk Slips After Data for Next-gen Obesity Drug
Weight-loss Drug Battle: Who Are the Latest Players Involved
William Blair Maintains Structure Therapeutics(GPCR.US) With Buy Rating
Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $60
Structure Therapeutics, Inc.: Strong Pipeline and Financial Stability Underpin Buy Rating Despite Price Target Reduction
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $50 to $100
Citizens Capital Markets Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $87
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $80 to $93
Express News | William Blair Initiates Coverage On Structure Therapeutics With Outperform Rating
Structure Therapeutics Analyst Ratings
Promising Potential of Structure Therapeutics' Aleniglipron: A Compelling Buy Recommendation
Buy Rating for Structure Therapeutics: Promising Phase 2b Trials and Strong Financial Position
Express News | Structure Therapeutics FY 2024 GAAP EPS $(0.78) Beats $(0.80) Estimate